Boston Scientific CORP Form 4 insider transactions

Boston Scientific's CEO, Michael Mahoney, reported a transaction involving the disposal of 7,800 shares of common stock held in trust.

Joseph Michael Fitzgerald, an EVP at Boston Scientific, reported the disposal of 12,349 shares and indirect ownership of 4,894 shares held by his child.

A Boston Scientific executive, Arthur C. Butcher, exercised stock options and sold shares under a pre-established 10b5-1 trading plan.

A Boston Scientific director, Edward J. Ludwig, sold 4,877 shares of common stock at a price of $91.6346 per share on November 21, 2024.

John Bradley Sorenson, EVP of Global Operations at Boston Scientific, reported a transaction involving 2,610 shares of common stock.

A Boston Scientific executive, John Bradley Sorenson, exercised stock options and sold shares under a pre-established 10b5-1 trading plan.

Michael Mahoney, Chairman, President & CEO of Boston Scientific, exercised stock options and sold shares of common stock on November 5, 2024, according to a pre-established Rule 10b5-1 trading plan.

Wendy Carruthers, EVP of Human Resources at Boston Scientific, executed stock options and sold shares under a pre-established Rule 10b5-1 trading plan.

Michael Mahoney, Chairman, President & CEO of Boston Scientific, exercised stock options and sold shares of common stock under a pre-established Rule 10b5-1 trading plan.

Executive Vice President of Boston Scientific, Joseph Michael Fitzgerald, exercised stock options and sold shares of common stock under a pre-established Rule 10b5-1 trading plan.

Wendy Carruthers, EVP of Human Resources at Boston Scientific, executed stock options and sold shares under a pre-established Rule 10b5-1 trading plan.

Michael Mahoney, Chairman, President & CEO of Boston Scientific, exercised stock options and sold shares of common stock under a pre-established Rule 10b5-1 trading plan.

EVP of Human Resources at Boston Scientific, Wendy Carruthers, exercised stock options and sold shares of common stock under a pre-established Rule 10b5-1 trading plan.

Michael Mahoney, Chairman, President & CEO of Boston Scientific, reported changes in his beneficial ownership of company stock due to gifts to and from trusts.

Joseph Michael Fitzgerald, EVP & Group President of Cardiology at Boston Scientific, sold 14,132 shares of common stock at $80 per share on August 28, 2024, under a pre-established Rule 10b5-1 trading plan.

Arthur C. Butcher, an Executive Vice President at Boston Scientific, reported the acquisition and disposal of company stock and derivative securities on August 26, 2024, according to a pre-established Rule 10b5-1 trading plan.

Arthur C. Butcher, EVP & Group President at Boston Scientific, reports acquiring shares of common stock through a 401(k) rebalancing and the Employee Stock Purchase Plan.

Director David C. Habiger received stock grants from Boston Scientific following his appointment to the Board of Directors.

Wendy Carruthers, EVP of Human Resources at Boston Scientific, exercised stock options and sold shares of common stock under a pre-established Rule 10b5-1 trading plan.

Vance R. Brown, SVP, GC, and Corp. Secretary of Boston Scientific, reports the acquisition and disposal of common stock and restricted stock units on July 1, 2024.

Wendy Carruthers, EVP of Human Resources at Boston Scientific, reports exercising stock options and selling shares under a pre-established Rule 10b5-1 trading plan.

Cheryl Pegus, a director of Boston Scientific Corp, was granted deferred stock units following her initial appointment to the Board of Directors.

EVP of Human Resources at Boston Scientific, Wendy Carruthers, exercised stock options and sold shares of common stock under a pre-established Rule 10b5-1 trading plan.

Executive Vice President of Boston Scientific, Jeffrey B. Mirviss, exercised stock options and sold shares of common stock according to a pre-established Rule 10b5-1 trading plan.

Arthur C. Butcher, an Executive Vice President at Boston Scientific, executed stock options and sold shares of common stock under a pre-established Rule 10b5-1 trading plan.

Daniel J. Brennan, EVP and CFO of Boston Scientific, exercised stock options and sold shares of common stock on May 22 and 23, 2024, under a pre-established Rule 10b5-1 trading plan.

Vance R. Brown, SVP, GC and Corp. Secretary of Boston Scientific, exercised stock options and sold shares of common stock on May 21 and 22, 2024, according to a Form 4 filing with the SEC.

Joseph Michael Fitzgerald, EVP & Group President of Cardiology at Boston Scientific, reports a gift of common stock and indirect ownership of shares held by a child.

Eric Francis Yves Thepaut, an EVP at Boston Scientific, exercised stock options and sold shares on May 10, 2024.

Director Ellen M. Zane acquired 2,901 shares of Boston Scientific common stock as an annual equity award.